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Abstract 
Background: Herpes zoster (HZ, shingles) is a frequent medical condition which may 
severely impact the quality of life of affected patients. Different therapeutic approaches to 
treat acute HZ are available.  
Objective: The aim of this European project was the elaboration of a consensus-based 
guideline on the management of patients who present with HZ, considering different patient 
populations and different localisations. This interdisciplinary guideline aims at an 
improvement of the outcomes of the acute HZ management concerning disease duration, 
acute pain and quality of life of the affected patients and at a reduction of the incidence of 
PHN and other complications.  
Methods: The guideline development followed a structured and predefined process, 
considering the quality criteria for guidelines development as suggested by the AGREE II 
instrument. The steering group was responsible for the planning and the organisation of the 
guideline development process (Division of Evidence based Medicine, dEBM). The expert 
panel was nominated by virtue of clinical expertise and/or scientific experience and included 
experts from the fields of dermatology, virology/infectiology, ophthalmology, otolaryngology, 
neurology and anaesthesiology. Recommendations for clinical practice were formally 
consented during the consensus conference, explicitly considering different relevant aspects. 
The guideline was approved by the commissioning societies after an extensive internal and 
external review process.   
Results: In this second part of the guideline, therapeutic interventions have been evaluated. 
The expert panel formally consented recommendations for the treatment of patients with HZ 
(antiviral medication, pain management, local therapy), considering various clinical 
situations.   
Conclusion: Users of the guideline must carefully check whether the recommendations are 
appropriate for the context of intended application. In the setting of an international guideline, 
it is generally important to consider different national approaches and legal circumstances 
with regards to the regulatory approval, availability and reimbursement of diagnostic and 
therapeutic interventions.  
Keywords: Clinical practice guideline, consensus statements, European guideline, herpes 
zoster, immunocompromized patients, postherpetic neuralgia, pregnancy, Ramsay-Hunt-
Syndrome, recommendations, shingles, zoster ophthalmicus, zoster oticus 
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Disclaimer 
Guidelines are intended to assist clinicians in standardized clinical situations. The final 
judgement with regards to the selection and administration of therapeutic interventions lies 
within the responsibility of the treating physician and must be individualized in light of all 
presenting circumstances. Users of the guideline must carefully check whether the 
recommendations are complete, correct, up-to-date and appropriate considering approval 
status, dosing regimes, mode of application, contra-indications, adverse effects and drug 
interactions. European guidelines are intended to be adapted to national circumstances (e.g. 
regarding regulatory approval, availability, reimbursement issues).  
 
Scope and purpose of the guideline 
The quality criteria for guidelines development as suggested by the Appraisal of Guidelines 
Research and Evaluation (AGREE II) Instrument1 were incorporated into the development of 
the guideline. Detailed information on the scope, purpose and methods is reported in the 
methods report (online supplement).  
Five strengths of recommendations were differentiated, expressed by wording and symbols 
(strong recommendation in favour, ↑↑ / weak recommendation in favour, ↑ / no 
recommendation, 0 / weak recommendation against, ↓ / strong recommendations against, 
↓↓)2. Table 1 shows wording, symbols and implications of each strength of recommendation. 
The percentage of agreement among the guideline’s expert panel was noted and reported 
(≥50%, ≥75%, ≥90%).  
Table 1: Strength of recommendation - wording, symbols and implications (modified from Andrews et 
al., 20132) 
Strength  Wording  Symbols  Implications 
Strong 
recommendation for 
the use of an 
intervention 
“We recommend 
…”  
↑↑ We believe that all or almost all informed people would 
make that choice. Clinicians will have to spend less time 
on the process of decision making, and may devote that 
time to overcome barriers to implementation and 
adherence. In most clinical situations, the 
recommendation may be adopted as a policy. 
Weak 
recommendation for 
the use of an 
intervention 
“We suggest …” ↑ We believe that most informed people would make that 
choice, but a substantial number would not. Clinicians 
and health care providers will need to devote more time 
on the process of shared decision making. Policy makers 
will have to involve many stakeholders and policy 
making requires substantial debate. 
 5 
European consensus-based (S2k) Guideline on the Management of Herpes zoster 
– guided by the EDF in cooperation with EADV [Part 2: Treatment] 
 
 
No recommendation 
with respect to an 
intervention 
“We cannot make 
a 
recommendation 
with respect to 
…” 
0 At the moment, a recommendation in favour or against 
an intervention cannot be made due to certain reasons 
(e.g. no reliable evidence data available, conflicting 
outcomes, etc.) 
Weak 
recommendation 
against the use of an 
intervention 
“We suggest 
against …” 
↓ We believe that most informed people would make a 
choice against that intervention, but a substantial 
number would not.  
Strong 
recommendation 
against the use of an 
intervention 
“We recommend 
against …” 
↓↓ We believe that all or almost all informed people would 
make a choice against that intervention. This 
recommendation can be adopted as a policy in most 
clinical situations. 
 
This second part of the guideline is devoted to the treatment of patients who present with HZ. 
It is divided into three sections:  
1) Antiviral medication [background texts and recommendations drafted by B. Marinović (lead 
author), A. F. Nikkels, A. M. Agius, Z. Bata-Csörgő, J. Breuer, G. E. Gross, R. Lapid-Gortzak, 
T. H. Lesser, U. Pleyer, P. Wutzler],  
2) Pain management [background texts and recommendations drafted by M. Schäfer (lead 
author), R. Lapid-Gortzak (co-lead author), Z. Bata-Csörgő, G. E. Gross], and  
3) Local therapy [background texts and recommendations drafted by M. Czarnecka-Operacz 
(lead author), A. F. Nikkels, A. M. Agius, R. Lapid-Gortzak, T. M. Lesser, U. Pleyer].  
The final recommendations were formally consented within the expert panel of the guideline. 
 
Antiviral medication 
General considerations for an antiviral medication 
In the absence of risk factors for complicated courses (see part 1 of the guideline), HZ 
usually is a self-limiting disease. Goals of treatment are to improve the outcomes concerning 
quality of life (QoL) of the affected patients, extent and duration of cutaneous symptoms, and 
intensity and duration of acute zoster-associated pain (ZAP). Since postherpetic neuralgia 
(PHN) is the most frequent sequela of HZ, reducing its incidence is a major secondary 
treatment goal. In immunosuppressed or otherwise susceptible patients, treatment goals 
extend to reducing the incidence and intensity of accompanying complications.  
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In controlled trials, a reduced duration of skin symptoms and duration or severity of ZAP 
could be demonstrated for the systemic application of aciclovir3-6, and famciclovir7 when 
compared to placebo. A meta-analysis of four placebo-controlled trials of oral aciclovir could 
demonstrate statically significant superiority over placebo regarding time to cessation of 
pain.8 Results from RCTs suggest superiority of valaciclovir over aciclovir considering 
duration and/or severity of ZAP9, 10. In these studies, no statistically significant differences 
were seen for the resolution of cutaneous symptoms. No statistically significant differences 
regarding pain cessation and resolution of skin symptoms were seen in RCTs comparing 
famciclovir with aciclovir11, 12, brivudin with aciclovir13, and valaciclovir with famciclovir14. One 
RCT, contrary to the previously mentioned trials, demonstrated superiority of famciclovir 
when compared to aciclovir regarding cessation of pain. However this difference only 
occurred in the 500mg famciclovir group and was of questionable clinical significance.15 
Another RCT, contrary to the previously mentioned trial on valaciclovir versus famciclovir, 
found a statistically significantly earlier reduction of pain with famciclovir.16  
QoL, as a central patient-reported outcome, was only addressed in a very limited number of 
trials. Due to the reduction of the duration and intensity of acute ZAP, it is presumed that an 
antiviral therapy may positively affect QoL. This presumption, however, is not based on 
scientific observations. 
A systematic review demonstrated that neither aciclovir nor famciclovir statistically 
significantly reduced the incidence of PHN four to six months after the onset of acute HZ 
when compared to placebo.17 Brivudin was compared with aciclovir in a survey study follow-
up of a previously conducted RCT13, which found a significantly lower incidence of PHN after 
brivudin than after aciclovir treatment.18 In an RCT comparing brivudin with famciclovir, 
however, no statistically significant between-group differences with respect to pain 
prevalence and duration were seen.19 
Regarding ocular complications of HZ ophthalmicus, pain duration and resolution of 
cutaneous symptoms, systemic application of aciclovir was favourable when compared to 
topical application of aciclovir in an RCT.20 No statistically significant differences were seen in 
RCTs of valaciclovir versus aciclovir21 and famciclovir versus aciclovir22.  
Controlled studies on antiviral medication have also been conducted in immunocompromised 
patients: One RCT compared the efficacy of intravenous aciclovir and placebo in 
immunocompromised patients with localized or disseminated HZ; here, aciclovir was superior 
considering a reduced incidence of complications (including cutaneous and visceral 
dissemination).23 Another RCT in 48 immunocompromised patients, comparing intravenous 
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aciclovir with oral brivudin did not find statistically significant differences regarding cutaneous 
or visceral dissemination.24 When compared to vidarabine, aciclovir was statistically 
significantly superior in preventing cutaneous dissemination, time until cessation of pain and 
healing of skin symptoms.25  
Based on consensus and in line with previous guidelines26, 27, the expert panel recommends 
the initiation of an antiviral medication in the presence of any of the conditions listed in 
recommendation #18 (Table 2). Due to the relatively low risk of complications associated 
with an antiviral medication, the initiation of an antiviral medication should also be considered 
in patients who are at low risk of sequelae or a complicated course (Table 2). 
Table 2: Health question 2, Antiviral medication, Recommendations #18 and #19 
Recommendation Supporting literature Strength Consensus 
#18 We recommend treating the following patient subgroups with 
an antiviral medication: 
- HZ of any localization in patients ≥ 50 years of age   
- HZ of the head and/or neck area 
- HZ of any localization with 
o moderate to severe zoster-associated pain 
o haemorrhagic or necrotizing lesions 
o >1 segment involved 
o aberrant vesicles / satellite lesions 
o involvement of mucous membranes 
- Zoster in immunocompromised patients  
- Zoster in patients with severe predisposing skin 
diseases (e.g. atopic dermatitis)  
- Zoster in children and adolescents under long-term 
treatment with  salicylic acid or corticosteroids 
Clinical 
consensus; 
Tyring et al. 
19957; 
McKendrick et 
al. 19863; Huff 
et al. 19884; 
Wood et al. 
19885; Beutner 
et al. 19959; Lin 
et al. 200110; 
Shen et al. 
200411; 
Shafran et al. 
200412; 
Wassilew et al. 
200313; Tyring 
et al. 200014; 
Degreef et al. 
199415; Ono et 
al. 201216; 
Balfour et al. 
198323; Wutzler 
et al. 199524; 
Shepp et al. 
198625 
↑↑ ≥ 90 % 
#19 In patients younger than 50 years of age who present with HZ 
of the trunk or extremities, without being at risk of or displaying 
signs of a complicated course, we suggest initiating an 
antiviral medication. 
↑ ≥ 90 % 
 
Based on consensus, an antiviral therapy using intravenous aciclovir is suggested in patients 
who present with complicated HZ or who are at risk of a complicated course (conditions 
specified in recommendation #20, Table 3). 
Table 3: Health question 2, Antiviral medication, Recommendation #20 
Recommendation Supporting literature Strength Consensus 
#20 We suggest using intravenous aciclovir in patients who 
present with complicated HZ or who are at risk of a 
complicated course. This includes the following patient groups: 
- HZ of the head and/or neck area, particularly in 
Clinical 
consensus ↑ ≥ 90 % 
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elderly patients 
- HZ with haemorrhagic/necrotizing lesions, >1 
segment involved, aberrant vesicles / satellite 
lesions,  involvement of mucous membranes, or 
generalized zoster 
- HZ in immunocompromised patients 
- HZ with signs of visceral or central nervous system 
involvement (dosage escalation up to 15mg/kg 
bodyweight 3x/d possible, treatment for up to 21 
days) 
 
Allthough limited evidence suggests superior efficacy of valaciclovir, famciclovir and brivudin 
over orally administered aciclovir regarding different outcomes, this evidence was not 
consistently reproduced. Brivudin offers the advantage of a reduced dosing frequency. 
However, other factors should also be considered in choosing among an antiviral medication 
(Table 4). Costs are the lowest for aciclovir. Brivudin is not available in all countries. It is 
contraindicated for immunosuppressed patients and patients who have been treated with 5-
fluoropyrimidine drugs (e.g. 5-fluorouracil, flucytosin) within the last 4 weeks due to possible 
life-threatening drug-interactions. 
Table 4: Health question 2, Antiviral medication, Recommendation #21 
Recommendation Supporting literature Strength Consensus 
#21 In patients who do not present with an indication to initiate an 
intravenous treatment with aciclovir, we suggest shared 
decision making with respect to using oral aciclovir, 
valaciclovir, famciclovir or brivudin, taking e.g. practicabilty 
(dosage frequency), costs, contraindications, comorbidity and 
drug interactions into consideration.  
Clinical 
consensus ↑ ≥ 90 % 
 
Adaptation of dosages to the renal function according to the product information is necessary 
for aciclovir, valaciclovir and famciclovir. For these agents, creatinine should be checked in 
patients with known or suspected renal insufficiency at the time of treatment initiation (Table 
5). 
Table 5: Health question 2, Antiviral medication, Recommendation #22 
Recommendation Supporting literature Strength Consensus 
#22 We suggest checking creatinine in patients with known or 
suspected renal insufficiency at the time of initiation of an 
antiviral medication with aciclovir, famciclovir, or valaciclovir. 
Clinical 
consensus ↑ ≥ 90 % 
 
Due to the lack of trials evaluating the initiation of a systemic antiviral medication more than 
72 hours after onset of the rash, there is no evidence basis to recommend the administration 
of antivirals in this setting. Based on consensus and as recommended in guidelines 
previously26, 27, we suggest an initiation of an antiviral medication at a later point in time in the 
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presence of any of the conditions listed in recommendation #23 (Table 6), if treatment within 
72 hours after the onset of cutaneous symptoms was not possible.  
Table 6: Health question 2, Antiviral medication, Recommendations #23 and #24 
Recommendation Supporting literature Strength Consensus 
#23 We suggest initiating antiviral medication as early as possible, 
within 72 hours after the onset of symptoms, or at a later time  
- as long as new vesicles appear 
- in patients at risk of a complicated course or with 
manifest complications 
- in patients with signs of cutaneous, visceral or 
neurological dissemination 
- in the case of HZ ophthalmicus or HZ oticus 
- in all immunocompromised patients 
Clinical 
consensus ↑ ≥ 90 % 
#24 We suggest against initiating an antiviral medication in 
patients who have ‘uncomplicated’ HZ (classical, unilateral 
thoracic or lumbar HZ in patients younger than 50 years of 
age, without signs of a complicated course) who present >72 
hours after the onset of skin symptoms. 
Clinical 
consensus ↓ ≥ 90 % 
 
There are few trials evaluating whether an extended period of intake of antivirals provides 
benefit over the standard administration for seven days. These trials found no clinically 
relevant difference9 or a benefit of questionable clinical importance with prolongued 
treatment28. Antiviral medication should be prolongued until no more vesicular lesions 
appear. If vesicle formation extends to more than seven days, the diagnosis should be 
reassessed and resistancy to the antiviral medication considered.   
 
Specific situations 
Renal function impairment 
For HZ in patients with renal function impairment, we suggest initiating an antiviral 
medication with brivudin in the case of indication for oral treatment or with intravenous 
aciclovir with dosage adaptation in the case of indication for intravenous treatment as defined 
above (Table 7). This recommendation is based on consensus among the expert panel and 
on the reasoning that brivudin is relatively less dependent on renal excretion than other 
antiviral agents and intravenous (in-patient) treatment with aciclovir allows for close 
examinations of the renal function during the course of treatment. 
Table 7: Health question 2, Antiviral medication, Recommendation #25 
Recommendation Supporting literature Strength Consensus 
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#25 In patients with renal function impairment, we recommend 
using oral brivudin (if oral antiviral medication is indicated) or 
intravenous aciclovir with dosage adaptation (if intravenous 
treatment is indicated as defined above). 
Clinical 
consensus ↑↑ ≥ 90 % 
 
Ophthalmic HZ 
The treatment strategy in case of HZ ophthalmicus and necessity for an ophthalmologic 
reassessment should be determined by an ophthalmologist. Generally, treatment 
recommendations as specified above apply. Acute retinal necrosis (ARN) as complication of 
HZ ophthalmicus is an ophthalmic emergency that has to be managed under close 
supervision of an ophthalmologist. Since ARN is rapidly progressive and may spread to the 
contralateral eye, it requires immediate treatment with an intravenous induction and oral 
treatment continuation of antivirals for 3–4 months (Table 8). The prolonged treatment is 
recommended in order to prevent involvement of the second eye.29, 30 The additional use of 
systemic corticosteroid in these patients is still controversial in respect to its appropriate 
initiation. A loading dose of 0.5-1.0 mg/kg/day of corticosteroids (prednisolone) for the first 7–
10 days of treatment has been suggested30, 31. We suggest using topical and systemic 
corticosteroids as adjunctive anti-inflammatory treatment (Table 8). Caution should be taken 
to use corticosteroids in the absence of antiviral medication, since this may promote viral 
replication and even initiate ARN. 
Table 8: Health question 2, Antiviral medication, Recommendations #26 and #27 
Recommendation Supporting literature Strength Consensus 
#26 In patients who present with acute retinal necrosis (as 
complication of HZ ophthalmicus), we recommend induction 
treatment with intravenous aciclovir (10mg/kg bodyweight 3x/d 
for 7-10 days)* followed by oral aciclovir (800mg 5x/d for 3-4 
months)*. 
*Dosage adaptation may be necessary 
Wong et al. 
201330; Pleyer 
et al. 201529 
↑↑ ≥ 90 % 
#27 In patients who present with acute retinal necrosis (as 
complication of HZ ophthalmicus), we suggest to use topical 
and systemic corticosteroids as adjunctive anti-inflammatory 
treatment. 
Wong et al. 
201330; 
Tibbetts et al. 
201031 
↑ ≥ 75 % 
 
Otic HZ 
The treatment strategy in case of HZ oticus with involvement of the facial nerve (i.e. Ramsay-
Hunt syndrome) or with severe pain and cranial nerve palsies should be determined by an 
otorhinolaryngologist. The expert panel suggests initiating a combination therapy of 
intravenous aciclovir and oral corticosteroids (Table 9). Corticosteroids are still considered 
 11 
European consensus-based (S2k) Guideline on the Management of Herpes zoster 
– guided by the EDF in cooperation with EADV [Part 2: Treatment] 
 
 
the best treatment in viral inflammatory processes of the facial nerve.32 In HZ oticus with 
severe pain and cranial nerve palsies, intravenous aciclovir followed by oral treatment for 
one to two weeks has been used with success.33-35 Combination treatment is more effective 
in restoring facial nerve function after HZ oticus36 and seems to offer better prognosis.37 
Table 9: Health question 2, Antiviral medication, Recommendation #28 
Recommendation Supporting literature Strength Consensus 
#28 In patients with HZ oticus with involvement of the facial nerve 
(Ramsay-Hunt syndrome) or with severe pain and multiple 
cranial nerve palsies, we suggest combination therapy of 
intravenous aciclovir with systemic corticosteroids. 
de Ru et al. 
201136; 
Coulson et al. 
201137 
↑ ≥ 90 % 
 
Pregnancy 
Due to the lack of systematically assessed data on the safety of antiviral medications during 
pregnancy, careful consideration of possible harms and benefits is recommended. In the 
absence of the risk of complications (see part 1 of the guideline), we suggest against 
initiating an antiviral medication in pregnant women who present with HZ (Table 10). In a 
large population-based retrospective controlled cohort study and in a study including data 
from registries, the risk of birth defects in children whose mothers had been exposed to 
aciclovir was not increased. For other antiviral agents (valaciclovir and famciclovir), the 
number of cases was too small to draw conclusions.38, 39 Therefore, the initiation of an 
antiviral medication in pregnant women using aciclovir may be suggested in the presence of 
risk factors for complicated courses of disease, if potential benefits to the mother outweigh 
the potential risks to the fetus (Table 10). 
Table 10: Health question 2, Antiviral medication, Recommendations #29 and #30 
Recommendation Supporting literature Strength Consensus 
#29 In the absence of the risk of complications, we suggest 
against initiating an antiviral medication in pregnant women. 
Clinical 
consensus ↓ ≥ 90 % 
#30 We suggest the initiation of an antiviral medication in pregnant 
women in the presence of risk factors for complicated courses 
of disease, if potential benefits to the mother outweigh the 
potential risks to the fetus. In this case, aciclovir should be 
used preferentially. 
Clinical 
consensus, 
Pasternak et al. 
201038; Reiff-
Eldridge et al. 
200039 
↑ ≥ 90 % 
 
Children 
Due to the lack of data on the safety in children, we recommend careful consideration of 
possible harms and benefits of an antiviral medication. Generally, HZ in children presents 
with less morbidity than HZ in adults.40, 41 In the absence of the risk of complications (see part 
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1 of the guideline), we suggest against initiating an antiviral medication in children (Table 11). 
The initiation of an antiviral medication in children is suggested in the presence of risk factors 
for complicated courses of disease, if potential benefits outweigh the potential risks (Table 
11). 
Table 11: Health question 2, Antiviral medication, Recommendations #31 and #32 
Recommendation Supporting literature Strength Consensus 
#31 In the absence of the risk of complications, we suggest 
against initiating an antiviral medication in children. 
Clinical 
consensus ↓ ≥ 90 % 
#32 We suggest the initiation of an antiviral medication in children 
in the presence of risk factors for complicated courses of 
disease, if potential benefits of the treatment outweigh the 
potential risks. 
Clinical 
consensus ↑ ≥ 90 % 
 
Therapy refractory / chronic HZ lesions 
Clinical resistance of VZV infections to aciclovir should be considered in case of treatment 
failure of drug therapy for at least 10 to 21 days42, 43, particularly in patients presenting 
verrucous VZV infections44. When aciclovir resistance occurs, treatment with alternative 
medications, e.g. with brivudin or another TK dependent antiviral agent (famciclovir) may be 
required. In small retrospective case series of immunocompromised patients with aciclovir-
resistant HZ, a response to intravenous foscarnet therapy has been observed.42, 45 Anecdotal 
reports exist which demonstrate responses of aciclovir-resistant VZV-strains to cidofovir.46-48 
Both agents are not licensed for the treatment of HZ. They should only be used in very 
severe cases, with caution due to the risk of severe adverse effects, and only following 
discussion with virologists, pharmacists and intensive discussion of the risk-benefit balance 
with the patient. In the case of chronic HZ lesions, we refer to a review article by Wauters et 
al (2012)44 on chronic mucocutaneous HZ lesions.  
 
Acute pain management 
Introduction 
HZ rash is often preceded and accompanied by continuous or episodic sensory sensations 
such as pain, paresthesias (e.g. burning and tingling), dysesthesia (altered or painful 
sensitivity to touch), allodynia (pain associated with nonpainful stimuli), or hyperesthesia 
(exaggerated or prolonged response to painful stimuli).49, 50 Acute ZAP occurs in ≥95% of 
patients aged >50 years, and 60-70% of patients continue to have persistent pain one month 
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after the episode, 40% of those considering it severe51. 52. While there is abundant literature 
on PHN53, 54, evidence on the treatment of acute ZAP is scarce. 
Assessment of pain 
Pain intensity should be assessed by a validated assessment scale [e.g. Visual Analog Scale 
or Numeric Rating Scale (NRS)]55, 56 (Table 12). Additionally, validated assessment tools may 
be used to assess neuropathic pain characteristics [Douleur Neuropathique 4 (DN4), 
PainDETECT (PD-Q), or Leeds Assessment of Neuropathic Symptoms and Signs 
(LANSS)]55, 56 and QoL [SF36 or short form SF12]55, 56.  
Table 12: Health question 3, Pain management, Recommendations #33 and #34 
Recommendation Supporting literature Strength Consensus 
#33 We recommend assessing pain intensity by a validated 
pain assessment scale, e.g. Visual Analog Scale, Numeric 
Rating Scale (0 = no pain, 10 = worst possible pain). 
Clinical consensus, 
Erlenwein et al., 
201655; Haanpää et 
al., 201156 
↑↑ ≥ 90 % 
#34 We suggest using additional tools (questionnaires) in 
selected patients as described in the background text. 
Clinical consensus, 
Erlenwein et al., 
201655; Haanpää et 
al., 201156 
↑ ≥ 90 % 
 
Further tools may be used to assess response to treatment [e.g. minimum and maximum 
pain during the last 24 hours, pain intensity during movement, and satisfaction with pain 
management (NRS, 0, not satisfied to 10, very satisfied)55, 56 (Table 13). Such tools have 
been recently validated for acute postoperative pain Europe wide57. 
Table 13: Health question 3, Pain management, Recommendation #35 
Recommendation Supporting literature Strength Consensus 
#35 We suggest assessing patients’ satisfaction with pain 
management (NRS: 0 = not satisfied to 10 = very 
satisfied). 
Clinical consensus, 
Erlenwein et al., 
201655; Haanpää et 
al., 201156 
↑ ≥ 75% 
 
Treatment of acute zoster-associated pain 
Apart from improving functional status and health-related QoL, controlling acute ZAP is 
presumed to reduce the risk of PHN, although evidence from controlled studies to support 
this presumption is not available. Distinct to the treatment of PHN, acute ZAP should 
preferentially be treated by systemic analgetics and not by local agents (Table 14). It should 
be taken into account that a process of neuroinflammation is in part responsible for the 
painful sensations58, 59. 
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Table 14: Health question 3, Pain management, Recommendation #36 
Recommendation Supporting literature Strength Consensus 
#36 We recommend an early initiation of acute ZAP treatment, 
using systemic analgesics. Clinical consensus ↑↑ ≥ 90 % 
 
Analgetic treatment of acute ZAP should follow the three-step WHO pain ladder60 as based 
on the severity of pain (Table 15) and the individual considerations: in situations of mild pain 
intensity, NSAIDs or other non-opioids are appropriate; with moderate pain, non-opioids in 
combination with weak opioid analgetics might be sufficient; with severe pain, non-opioids 
combined with strong opioids may be required27, 55, 61. Treatment should start according to the 
severity of pain and not follow a time-consuming stepwise approach61. Because of the 
neuropathic component of pain, tricyclic antidepressant (e.g. amitriptyline) or antiepileptic 
drugs (e.g. gabapentin, pregabalin) may be added as supplement to the basic analgetic 
treatment60, 62. Effective plasma concentrations are reached after several days and thus, the 
basic analgesic treatment should not be postponed. The mentioned antidepressants and 
antiepileptic drugs may not be approved for the indication of acute ZAP treatment. 
Supplementing pain medication should be considered if pain severity at baseline is moderate 
to severe or other risk factors for PHN are present (Table 15). The individual risk for PHN 
may be estimated taking various prognostic factors into account as suggested by Meister et 
al. 199863: female gender, age > 50 years, number of lesions > 50, cranial / sacral 
localisation, haemorrhagic lesions, and dermatomal pain in the prodromal phase. 
Table 15: Health question 3, Pain management, Recommendation #37 
Recommendation Supporting literature Strength Consensus 
#37 We recommend analgesic treatment of HZ pain 
according to the WHO pain ladder60 and, if pain severity at 
baseline is moderate to severe or other risk factors for 
PHN are present, consider supplementing with an 
antidepressant (e.g. amitriptyline) or antiepileptic (e.g. 
gabapentin, pregabalin) drug*. 
*The mentioned antidepressants and antiepileptic drugs 
may not be approved for the treatment of acute zoster-
associated pain. 
Clinical consensus ↑↑ ≥ 90 % 
 
Treatment of ZAP should aim at an optimal pain relief, or if not attainable, at a reduction of 
pain to a level acceptable for the patient. A follow-up of patients with acute ZAP is 
suggested, including the period after resolution of skin lesions. In case of persisting pain not 
acceptable for the patient, a referral to a pain specialist is recommended (Table 16). 
Table 16: Health question 3, Pain management, Recommendation #38 
Recommendation Supporting Strength Consensus 
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literature 
#38 We recommend referral to a pain specialist in the case of 
persisting pain (e.g. after 4 weeks after the resolution of 
skin lesions). 
Clinical consensus ↑↑ ≥ 90 % 
 
 
Local therapy 
General considerations 
There is insufficient evidence and expert agreement to make recommendations for a specific 
topical treatment of acute HZ (Table 17). Clinical practices vary largely among different 
countries. For all topical treatment decisions, the current status of the skin needs to be 
assessed. Some experts from the group apply sterile saline 0.9% solution, or mild antiseptics 
such as polihexanide 20% solution to the affected area for 20 to 30 Minutes four to six times 
daily. The application of local zinc oxide lotion is common practice at some centers. Some 
experts recommend to refrain from any topical treatment but to keep the lesions clean and 
dry.    
Table 17: Health question 3, Local therapy, Recommendation #39 
Recommendation Supporting literature Strength Consensus 
#39 We suggest selecting a topical treatment according to the 
current status of the skin lesions. Clinical consensus ↑ ≥ 75% 
 
The topical application of antiviral agents remains a matter of debate in case of HZ of the 
trunk and extremities. There are no placebo-controlled RCTs to support using these agents 
(Table 18). 
Table 18: Health question 3, Local therapy, Recommendation #40 
Recommendation Supporting literature Strength Consensus 
#40 We cannot make a recommendation with respect to the 
application of local antiviral preparations for cutaneous 
herpes zoster. 
- 0 ≥ 90% 
 
The topical application of local anaesthetics or capsaicin cream is not advocated. A 
systematic review of topical lidocaine for the treatment of neuropathic pain64 concluded that 
there is no evidence from high quality studies to support its use. Based on consensus, the 
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expert panel recommends treating acute ZAP according to the above-mentioned 
recommendations, using systemic analgetics (Table 19). 
Table 19: Health question 3, Local therapy, Recommendation #41 
Recommendation Supporting literature Strength Consensus 
#41 We suggest against the application of local anaesthetic 
agents or capsaicin for acute HZ. 
Clinical consensus, 
Derry et al. 201464 ↓ ≥ 90% 
 
Specific situations 
The optimal topical treatment strategy for HZ ophthalmicus remains controversial since RCTs 
have shown conflicting results: In one RCT assessing the efficacy of topical aciclovir versus 
betamethasone in zoster-associated keratouveitis, ocular symptoms resolved significantly 
quicker and recurrences ocurred less frequently in the aciclovir-treated group.65  In another 
RCT, a prolongued time to resolution of ocular inflammation was seen when compared to 
steroid treatment.66 Based on consensus, the expert panel recommends the application of 
ocular aciclovir preparations to the affected eye five times daily (Table 20), particularly in 
case of VZV-associated dendriform keratitis. Topical steroids should be used with caution in 
staining epithelial lesions.  
In disciform keratitis, endotheliitis and anterior uveitis, topical steroids are the mainstay of 
treatment (Table 20). Steroids need to be used with caution and under close supervision of 
an ophthalmologist, as the disease process may cause thinning and even perforation of the 
cornea, secondary glaucoma, and superinfection of reactivated dendriform keratitis67.  
Table 20: Health question 3, Local therapy, Recommendations #42 and #43 
Recommendation Supporting literature Strength Consensus 
#42 In the case of HZ ophthalmicus, we recommend the 
application of local aciclovir preparations (e.g. aciclovir 3% 
ocular ointment) to the affected eye five times daily. 
Clinical consensus ↑↑ ≥ 90% 
#43 In the case of HZ ophthalmicus with disciform keratitis, 
endotheliitis or anterior uveitis, we recommend the 
application of topical steroids under the management of an 
ophthalmologist. 
Clinical consensus ↑↑ ≥ 90% 
 
For HZ oticus, evidence from trials supporting a specific topical treatment approach is not 
available. 
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